NEWS
Find a Professional: Explore Experts Across 197 Disciplines in 221 Countries!
Just Updated: Compare Your Institution (Live Data)
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025 (Updated Today)
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
Login
Register & Pricing
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Marco Montillo
Ospedale Niguarda Ca' Granda, Milan - Milano / Italy
Medical and Health Sciences / Hematology
AD Scientific Index ID: 4984848
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Co-Authors
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Marco Montillo's MOST POPULAR ARTICLES
1-)
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia New England Journal of Medicine 371 (3), 213-223, 2014
2-)
Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia New England Journal of Medicine 378 (12), 1107-1120, 2018
3-)
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic … Journal of clinical oncology 28 (10), 1756-1765, 2010
4-)
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia Journal of clinical oncology 27 (26), 4378-4384, 2009
5-)
Final analysis from RESONATE: up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma American journal of hematology 94 (12), 1353-1363, 2019
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept